TELESIS BIO INC (TBIO)
US1920032000 - Common Stock
Overall TBIO gets a fundamental rating of 1 out of 10. We evaluated TBIO against 55 industry peers in the Life Sciences Tools & Services industry. TBIO has a bad profitability rating. Also its financial health evaluation is rather negative. TBIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year TBIO has reported negative net income.
TBIO had a negative operating cash flow in the past year.
In the past 5 years TBIO always reported negative net income.
TBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TBIO has a Return On Assets of -98.37%. This is amonst the worse of the industry: TBIO underperforms 92.98% of its industry peers.
The Return On Equity of TBIO (-521.49%) is worse than 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -98.37% | ||
| ROE | -521.49% | ||
| ROIC | N/A |
ROA(3y)-54.24%
ROA(5y)-50.23%
ROE(3y)-104.32%
ROE(5y)-94.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TBIO's Gross Margin of 47.88% is in line compared to the rest of the industry. TBIO outperforms 54.39% of its industry peers.
In the last couple of years the Gross Margin of TBIO has grown nicely.
The Profit Margin and Operating Margin are not available for TBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.78%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBIO has been increased compared to 1 year ago.
Compared to 1 year ago, TBIO has an improved debt to assets ratio.
2.2 Solvency
TBIO has an Altman-Z score of -6.48. This is a bad value and indicates that TBIO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TBIO (-6.48) is worse than 91.23% of its industry peers.
TBIO has a Debt/Equity ratio of 0.54. This is a neutral value indicating TBIO is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.54, TBIO is doing worse than 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.48 |
ROIC/WACCN/A
WACC14.42%
2.3 Liquidity
TBIO has a Current Ratio of 1.89. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of TBIO (1.89) is worse than 61.40% of its industry peers.
TBIO has a Quick Ratio of 1.72. This is a normal value and indicates that TBIO is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.72, TBIO perfoms like the industry average, outperforming 45.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
The earnings per share for TBIO have decreased strongly by -1673.33% in the last year.
The Revenue for TBIO has decreased by -43.65% in the past year. This is quite bad
TBIO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 61.13% yearly.
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2621.43%
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5YN/A
Sales Q2Q%-82.09%
3.2 Future
The Earnings Per Share is expected to decrease by -29.72% on average over the next years. This is quite bad
TBIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -40.92% yearly.
EPS Next Y-122.26%
EPS Next 2Y-29.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-66.55%
Revenue Next 2Y-40.92%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
TBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TBIO's earnings are expected to decrease with -29.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.72%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for TBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TELESIS BIO INC
NASDAQ:TBIO (9/27/2024, 8:22:41 PM)
After market: 2.85 -0.38 (-11.76%)3.23
-0.76 (-19.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.72M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -98.37% | ||
| ROE | -521.49% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.88% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-1673.33%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-122.26%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-43.65%
Revenue growth 3Y61.13%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y